This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
1,357 AI medical devices cleared, 3 actually tested on patient outcomes
Rawan Abulibdeh, et al.. PLOS Digital Health, 2026.
DOI: 10.1371/journal.pdig.0001597
-
Explainable Machine Learning Model to Predict High-Grade Adverse Events in Neoadjuvant Chemo-Immunotherapy for NSCLC: A Multicenter Study
Weekly News Brief: September 14–18, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of September 14–18, 2026.
This week’s brief covers an explainable machine learning model for predicting high-grade adverse events from neoadjuvant chemoimmunotherapy for patients with non–small cell lung cancer, and a review of FDA-authorized AI-enabled medical devices and their supporting clinical evidence.
To learn more about machine learning for predicting TRAEs, read "Machine Learning Model Assesses Toxicity Risk During Neoadjuvant Chemoimmunotherapy for NSCLC," or see the meeting abstract.
For more information on a review of FDA-authorized AI medical devices, read "FDA-Cleared AI Faces an Evidence Gap," or see the source report in PLOS Digital Health.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.